The present disclosure provides immunomodulatory fusion proteins-metal hydroxide complexes comprising an immunomodulatory domain adsorbed to a metal hydroxide via ligand exchange. The disclosure also features compositions and methods of using the same, for example, to treat cancer.

The present application provides a chimeric antigen receptor and application thereof. The chimeric antigen receptor comprises an antigen-binding domain, a transmembrane domain, a costimulatory signal transduction region, a CD3 signal transduction domain, and an inducible suicide fusion domain in tandem arrangement; wherein the antigen-binding domain binds to a tumor surface antigen and the tumor surface antigen is CD19.

Provided are methods for recombinantly producing enzymatically active glycosyltransferase (GT) enzymes. Active recombinant glycosyltransferase enzymes and method of use thereof are also provided. The methods for recombinantly producing enzymatically active GTs relies on a yeast expression system, preferably, a Pichia pastoris, expression system and more preferably, a Pichia pastoris stain with an ade2 deletion. Recombinantly produced enzymatically active GT enzymes produced according to the methods disclosed herein can be used for cell surface glycan engineering. The method includes contacting a cell with the disclosed compositions comprising purified recombinant GT enzyme and a substrate (nucleotide sugar) for the GT enzyme for an effective time for the GT enzyme to catalyze transfer of its substrate onto an acceptor site at the surface of the cell. The composition in preferred embodiments does not include glycerol as a stabilizer or it includes at least 50% glycerol.

The present invention provides compositions and methods for inducing allogenic tumor rejection and, more particularly, but not exclusively, compositions and methods employing fusion proteins comprising an MHC class I HLA amino acid sequence mismatched to the host.

The present invention provides materials and methods useful for error correction of nucleic acid molecules. In one embodiment of the invention, a first plurality of double-stranded nucleic acid molecules having a nucleotide mismatch are fragmented by exposure to a molecule having unidirectional mismatch endonuclease activity. The nucleic acid molecules are cut at the mismatch site or near the mismatch site, leaving a double-stranded nucleic acid molecule having a mismatch at the end or near end of the molecule. The nucleic acid molecule is then exposed to a molecule having unidirectional exonuclease activity to remove the mismatched nucleotide. The missing nucleotides can then be filled in by the action of, e.g., a molecule having DNA polymerase activity. The result is double-stranded nucleic acid molecules with a decreased frequency of nucleotide mismatches. Also provided are novel nucleic acid sequences encoding mismatch endonucleases, polypeptides encoded thereby, as well as nucleic acid constructs, transgenic cells, and various compositions thereof.

Disclosed are compositions and methods for expressing and purifying a peptide of interest using a Flagellar Type III secretion system. Disclosed are nucleic acid sequences that contain a FlgM nucleic acid sequence, a cleavage site, and a nucleic acid sequence of interest. Also disclosed are polypeptides that contain FlgM, a cleavage site and a peptide of interest. Methods of producing polypeptides that have FlgM, a cleavage site and a peptide of interest are provided.

A method of immunizing a human against infection by parasitic worms, comprising orally administering a live attenuated recombinant bacterium, expressing at least one antigen corresponding to a parasitic worm antigen; and a sterile injectable vaccine comprising the at least one antigen corresponding to a parasitic worm antigen. The method is effective against worms, including schistosomes.

Methods of making recombinant secretion of silk and silk-amyloid proteins using bacteria are provided.

Provided herein, in some embodiments, are artificial secretion peptides capable of directing secretion from Lactobacillus for use, for example, in producing heterologous proteins, including therapeutic proteins.

The invention provides a dual VEGF/PDGF antagonist comprising a VEGF antagonist linked to a PDGF antagonist. The VEGF antagonist is an antibody to a VEGF or VEGFR or is a VEGFR extracellular trap segment (i.e., a segment from the extracellular region of one or more VEGFR receptors that inhibits binding of at least one VEGFR to at least one VEGF). The PDGF antagonist is an antibody to a PDGF or PDGFR or is a PDGFR extracellular trap segment (i.e., segment from the extracellular region of one or more PDGFRs, which inhibits binding of at least one PDGFR and at least one PDGF). The dual antagonist is preferably conjugated to a half-life extending moiety, such as a HEMA-PC polymer. The dual antagonist is particularly useful for treating wet aged related macular degeneration.